HDAC9 and neoplasm: Rational use of HDAC inhibitors, such as in conjunction with other treatments or in selected patients, could be leveraged to reduce tumor heterogeneity and thus mitigate tumor resistance and recurrence mechanisms (Figure 3, Table 2).